NO20093217L - Makrocykliske analoger og fremgangsmater for fremstilling og anvendelse derav - Google Patents
Makrocykliske analoger og fremgangsmater for fremstilling og anvendelse deravInfo
- Publication number
- NO20093217L NO20093217L NO20093217A NO20093217A NO20093217L NO 20093217 L NO20093217 L NO 20093217L NO 20093217 A NO20093217 A NO 20093217A NO 20093217 A NO20093217 A NO 20093217A NO 20093217 L NO20093217 L NO 20093217L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- processes
- macrocyclic analogues
- macrocyclic
- analogues
- Prior art date
Links
- 229930195695 Halichondrin Natural products 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8968298P | 1998-06-17 | 1998-06-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20093217L true NO20093217L (no) | 2001-02-15 |
| NO331183B1 NO331183B1 (no) | 2011-10-24 |
Family
ID=22219026
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20006316A NO328280B1 (no) | 1998-06-17 | 2000-12-12 | Makrocykliske analoger |
| NO20093217A NO331183B1 (no) | 1998-06-17 | 2009-10-26 | Farmasoytisk preparat omfattende en halokondrinanalog eller et farmasoytisk salt derav og en farmasoytisk akseptabel baerer |
| NO2011018C NO2011018I1 (no) | 1998-06-17 | 2011-09-16 | Eribulin og farmasøytisk akseptable salter derav |
| NO2011026C NO2011026I2 (no) | 1998-06-17 | 2011-12-14 | Eribulin eller et farmasøytisk akseptabelt salt derav |
| NO2022019C NO2022019I1 (no) | 1998-06-17 | 2022-06-03 | Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20006316A NO328280B1 (no) | 1998-06-17 | 2000-12-12 | Makrocykliske analoger |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2011018C NO2011018I1 (no) | 1998-06-17 | 2011-09-16 | Eribulin og farmasøytisk akseptable salter derav |
| NO2011026C NO2011026I2 (no) | 1998-06-17 | 2011-12-14 | Eribulin eller et farmasøytisk akseptabelt salt derav |
| NO2022019C NO2022019I1 (no) | 1998-06-17 | 2022-06-03 | Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US6214865B1 (no) |
| EP (4) | EP2277873B1 (no) |
| JP (1) | JP4454151B2 (no) |
| KR (1) | KR100798600B1 (no) |
| CN (1) | CN1216051C (no) |
| AT (1) | ATE502932T1 (no) |
| AU (1) | AU762998B2 (no) |
| BE (1) | BE2011C028I2 (no) |
| BR (1) | BRPI9911326B8 (no) |
| CA (3) | CA2335300C (no) |
| CY (2) | CY1111516T1 (no) |
| DE (2) | DE122011100031I1 (no) |
| DK (1) | DK1087960T3 (no) |
| FR (1) | FR11C0038I2 (no) |
| HU (1) | HU227912B1 (no) |
| IL (1) | IL139960A0 (no) |
| LU (1) | LU91854I2 (no) |
| NO (5) | NO328280B1 (no) |
| NZ (1) | NZ508597A (no) |
| PT (1) | PT1087960E (no) |
| WO (1) | WO1999065894A1 (no) |
| ZA (1) | ZA200007159B (no) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8097648B2 (en) * | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
| HU227912B1 (en) * | 1998-06-17 | 2012-05-29 | Eisai R & D Man Co | Halichondrin analogs and methods of their use and preparation |
| US6653341B1 (en) * | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| DE10037310A1 (de) | 2000-07-28 | 2002-02-07 | Asta Medica Ag | Neue Indolderivate und deren Verwendung als Arzneimittel |
| AU2003224644A1 (en) * | 2002-02-27 | 2003-09-09 | The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan | Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use |
| CA2479764C (en) | 2002-03-22 | 2013-07-30 | Eisai Co., Ltd. | Hemiasterlin derivatives and uses thereof |
| US20050075395A1 (en) * | 2003-05-28 | 2005-04-07 | Gary Gordon | Continuous dosing regimen |
| EP1644008B1 (en) * | 2003-05-29 | 2011-12-21 | Abbott Laboratories | Continuous dosing regimen with abt-751 |
| EP1653953A4 (en) * | 2003-07-29 | 2010-05-05 | Eisai R&D Man Co Ltd | METHOD AND DEVICES FOR THE MEDICINAL PRODUCTION |
| PL2522663T3 (pl) | 2004-06-03 | 2015-08-31 | Eisai R&D Man Co Ltd | Produkty pośrednie do otrzymywania halichondryny B |
| CN109180615A (zh) * | 2004-06-03 | 2019-01-11 | 卫材R&D管理有限公司 | 用于制备软海绵素b的类似物的中间体 |
| US20060045846A1 (en) * | 2004-08-30 | 2006-03-02 | Horstmann Thomas E | Reagents and methods for labeling terminal olefins |
| EP1831697A4 (en) * | 2004-12-09 | 2011-01-26 | Eisai R&D Man Co Ltd | SEARCH FOR TUBULINISOTYPES IN CANCER THERAPY USING HALICHONDRIN B ANALOG |
| CN108948039B (zh) | 2007-10-03 | 2021-12-31 | 卫材R&D管理有限公司 | 用于合成软海绵素b类似物的中间体和方法 |
| CN105801599A (zh) * | 2008-04-04 | 2016-07-27 | 卫材R&D管理有限公司 | 软海绵素b类似物 |
| HRP20161157T1 (hr) | 2009-03-30 | 2016-11-18 | Eisai R&D Management Co., Ltd. | Liposomski pripravak |
| RU2476216C1 (ru) * | 2009-03-30 | 2013-02-27 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Липосомальная композиция |
| EP2415464B1 (en) | 2009-03-30 | 2017-05-10 | Eisai R&D Management Co., Ltd. | Method for producing liposome composition |
| JP5556811B2 (ja) * | 2009-04-14 | 2014-07-23 | 日産化学工業株式会社 | テトラヒドロピラン化合物の製造方法 |
| BR112012003592B8 (pt) | 2009-08-19 | 2021-05-25 | Eisai R&D Man Co Ltd | composição farmacêutica contendo derivado de quinolina |
| CN102803254B (zh) | 2010-01-26 | 2016-09-14 | 卫材R&D管理有限公司 | 用于软海绵素b类似物合成的呋喃并[3,2-b]吡喃衍生物 |
| WO2012129100A1 (en) | 2011-03-18 | 2012-09-27 | Eisai R&D Management Co., Ltd. | Methods and compositions for predicting response to eribulin |
| WO2012147900A1 (en) | 2011-04-28 | 2012-11-01 | Eisai R&D Management Co., Ltd. | Microreactor process for halichondrin b analog synthesis |
| WO2012166899A2 (en) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| CA2857385A1 (en) | 2011-11-30 | 2013-06-06 | Alphora Research Inc. | Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene |
| US9174956B2 (en) | 2011-12-16 | 2015-11-03 | Alphora Research Inc. | Process for preparation of 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives and intermediates useful thereof |
| JP6300030B2 (ja) * | 2011-12-29 | 2018-03-28 | サンド アクツィエンゲゼルシャフト | ２−（（２ｓ，３ｓ，４ｒ，５ｒ）−５−（（ｓ）−３−アミノ−２−ヒドロキシプロプ−１−イル）−４−メトキシ−３−（フェニルスルホニルメチル）テトラヒドロフラン−２−イル）アセトアルデヒド誘導体およびこれらを調製するためのプロセス |
| US9278979B2 (en) | 2012-03-30 | 2016-03-08 | Alphora Research Inc. | Synthetic process for preparation of macrocyclic C1-keto analogs of halichondrin B and intermediates useful therein |
| MX2015007185A (es) | 2012-12-04 | 2017-09-05 | Eisai R&D Man Co Ltd | Uso de eribulina en el tratamiento de cancer de pecho. |
| AU2014268086A1 (en) | 2013-05-15 | 2015-11-05 | Alphora Research Inc. | 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof |
| AU2014299699B2 (en) | 2013-06-26 | 2019-10-10 | Eisai R&D Management Co., Ltd. | Use of eribulin and lenvatinib as combination therapy for treatment of cancer |
| US9850254B2 (en) | 2013-07-03 | 2017-12-26 | Sandoz Ag | Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing-SO2-(p-tolyl) groups |
| CN103483352A (zh) * | 2013-10-18 | 2014-01-01 | 李友香 | 抗肿瘤的药用原料药 |
| CN105683198B (zh) | 2013-11-04 | 2019-03-12 | 卫材R&D管理有限公司 | 软海绵素b的类似物合成中有用的大环化反应和中间体 |
| HUE043088T2 (hu) * | 2013-12-06 | 2019-08-28 | Eisai R&D Man Co Ltd | Halikondrin B analógok szintézisében alkalmazható eljárások |
| CN104860978A (zh) * | 2014-02-20 | 2015-08-26 | 正大天晴药业集团股份有限公司 | 软海绵素b类似物的合成中间体 |
| TW201617326A (zh) | 2014-03-06 | 2016-05-16 | Ａｌｐｈｏｒａ研發股份有限公司 | （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物 |
| JP2017516802A (ja) | 2014-05-28 | 2017-06-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がんの治療におけるエリブリンの使用 |
| EP3160970A4 (en) | 2014-06-30 | 2017-12-27 | President and Fellows of Harvard College | Synthesis of halichondrin analogs and uses thereof |
| CA2957005C (en) | 2014-08-28 | 2021-10-12 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| EP3191479B1 (en) * | 2014-09-09 | 2020-04-08 | Cipla Limited | "process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof" |
| CN105713031B (zh) * | 2014-12-05 | 2021-05-07 | 正大天晴药业集团股份有限公司 | 一种用于制备艾日布林的中间体及其制备方法 |
| SG11201706630UA (en) | 2015-02-25 | 2017-09-28 | Eisai R&D Man Co Ltd | Method for suppressing bitterness of quinoline derivative |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| KR20170122810A (ko) | 2015-03-04 | 2017-11-06 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 에리불린의 조합 |
| WO2016176560A1 (en) | 2015-04-30 | 2016-11-03 | President And Fellows Of Harvard College | Chromium-mediated coupling and application to the synthesis of halichondrins |
| RU2020141025A (ru) * | 2015-05-07 | 2020-12-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Реакции макроциклизации и промежуточные соединения и другие фрагменты, полезные в синтезе макролидов галихондринов |
| US10597401B2 (en) | 2015-05-08 | 2020-03-24 | Albany Molecular Research, Inc. | Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof |
| BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
| JP6553726B2 (ja) | 2015-08-20 | 2019-07-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| US10676481B2 (en) | 2016-02-12 | 2020-06-09 | Eisai R&D Management Co., Ltd. | Intermediates in the synthesis of eribulin and related methods of synthesis |
| WO2017188350A1 (ja) | 2016-04-28 | 2017-11-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍の成長を抑制する方法 |
| WO2017203459A1 (en) | 2016-05-26 | 2017-11-30 | Dr. Reddy's Laboratories Limited | Process for preparation of eribulin and intermediates thereof |
| SG11201811671XA (en) | 2016-06-30 | 2019-01-30 | Eisai R&D Man Co Ltd | Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof |
| EP3525818A1 (en) | 2016-10-14 | 2019-08-21 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer |
| JP6978758B2 (ja) | 2016-11-11 | 2021-12-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | パラジウム媒介ケトール化 |
| WO2018096478A2 (en) | 2016-11-23 | 2018-05-31 | Dr. Reddy’S Laboratories Limited | Process for preparation of eribulin and intermediates thereof |
| KR101880939B1 (ko) | 2017-01-02 | 2018-08-17 | 연성정밀화학(주) | 에리불린 메실산염의 제조 중간체 및 그의 제조방법 |
| JP6920699B2 (ja) * | 2017-01-02 | 2021-08-18 | ヨンスン ファイン ケミカル カンパニー，リミテッド | エリブリンメシル酸塩の製造中間体及びその製造方法 |
| KR101991710B1 (ko) | 2017-12-14 | 2019-06-21 | 연성정밀화학(주) | 에리불린 메실산염의 제조 중간체 및 그의 제조방법 |
| CN108341828B (zh) * | 2017-01-24 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | 用于制备艾日布林的方法及其中间体 |
| CN108341738B (zh) * | 2017-01-24 | 2022-10-21 | 江苏恒瑞医药股份有限公司 | 用于制备艾日布林的方法及其中间体 |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| KR102836514B1 (ko) | 2017-04-05 | 2025-07-22 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 마크로시클릭 화합물 및 그의 용도 |
| US9938288B1 (en) | 2017-04-05 | 2018-04-10 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
| BR112019023064A2 (pt) | 2017-05-16 | 2020-06-09 | Eisai R&D Man Co Ltd | tratamento de carcinoma hepatocelular |
| HUE061306T2 (hu) | 2017-07-06 | 2023-06-28 | Harvard College | Halikondrinok szintézise |
| US11498892B2 (en) | 2017-07-06 | 2022-11-15 | President And Fellows Of Harvard College | Fe/Cu-mediated ketone synthesis |
| US20190046513A1 (en) | 2017-08-10 | 2019-02-14 | Huya Bioscience International, Llc | Combination therapies of hdac inhibitors and tubulin inhibitors |
| CN109694379B (zh) * | 2017-10-24 | 2020-09-11 | 江苏恒瑞医药股份有限公司 | 用于制备艾日布林的中间体及其制备方法 |
| US11142509B2 (en) | 2017-11-09 | 2021-10-12 | Yonsung Fine Chemical Co., Ltd. | Intermediate for preparing eribulin mesylate and process for preparing the same |
| ES2974243T3 (es) | 2017-11-15 | 2024-06-26 | Harvard College | Compuestos macrocíclicos y usos de los mismos |
| EP3713565A1 (en) | 2017-11-20 | 2020-09-30 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| US11008296B2 (en) | 2017-11-21 | 2021-05-18 | Natco Pharma Limited | Intermediates for the preparation of eribulin thereof |
| KR20250057138A (ko) | 2018-01-03 | 2025-04-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 할리콘드린 마크롤리드 및 그의 유사체의 합성에 유용한 프린스 반응 및 화합물 |
| WO2019211877A1 (en) | 2018-05-03 | 2019-11-07 | Cipla Limited | Process for the preparation of macrocyclic ketone analogs of halichondrin b |
| WO2020008382A1 (en) * | 2018-07-04 | 2020-01-09 | Dr. Reddy’S Laboratories Limited | Process for preparation of eribulin and intermediates thereof |
| JP2021532102A (ja) * | 2018-07-20 | 2021-11-25 | ドクター レディズ ラボラトリーズ リミテッド | エリブリンおよびその中間体の調製のための精製プロセス |
| US20210340156A1 (en) * | 2018-10-09 | 2021-11-04 | Dr. Reddy's Laboratories Limited | Process for preparation of eribulin and intermediates thereof |
| WO2020110146A1 (en) * | 2018-11-28 | 2020-06-04 | Natco Pharma Limited | Process for the preparation of high pure eribulin and its mesylate salt |
| BR112021012138A2 (pt) | 2018-12-20 | 2021-08-31 | Auransa Inc. | Análogos de pentamidina e seus usos |
| US11447499B2 (en) | 2019-06-14 | 2022-09-20 | Rk Pharma Inc. | Process for the preparation of eribulin mesylate intermediate |
| WO2020255164A1 (en) | 2019-06-21 | 2020-12-24 | Council Of Scientific And Industrial Research | A chemo-enzymatic process for the preparation of homopropargylic alcohol |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| CN114729042B (zh) | 2019-11-07 | 2026-03-03 | 卫材R&D管理有限公司 | 抗间皮素艾日布林抗体-药物缀合物及使用方法 |
| CN113135876B (zh) * | 2020-01-16 | 2024-05-17 | 南通诺泰生物医药技术有限公司 | 艾日布林及其中间体的制备方法 |
| WO2021148003A1 (zh) * | 2020-01-22 | 2021-07-29 | 上海森辉医药有限公司 | 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用 |
| KR102377262B1 (ko) | 2020-05-11 | 2022-03-22 | 연성정밀화학(주) | 결정성 에리불린 염 |
| IL279168B (en) * | 2020-12-02 | 2022-04-01 | Finetech Pharmaceutical Ltd | A process for the preparation of eribulin |
| CN113354659B (zh) | 2021-06-08 | 2022-04-08 | 江苏慧聚药业股份有限公司 | 甲磺酸艾日布林的合成 |
| KR20240037267A (ko) * | 2021-07-22 | 2024-03-21 | 상하이 센후이 메디슨 컴퍼니 리미티드 | 에리불린 유도체의 약물 접합체 |
| WO2023212746A2 (en) * | 2022-04-30 | 2023-11-02 | William Marsh Rice University | A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b |
| KR20250133788A (ko) * | 2023-01-17 | 2025-09-08 | 시스트이뮨, 인코포레이티드 | 에리불린 약물 접합체 |
| WO2024251240A1 (zh) | 2023-06-09 | 2024-12-12 | 徕特康(苏州)生物制药有限公司 | 抗her2互补性双特异抗体-药物偶联物及其制备方法和用途 |
| CN118834221B (zh) * | 2023-08-08 | 2025-10-21 | 浙江星月药物科技有限公司 | 一种软海绵素b类似物 |
| TW202518024A (zh) | 2023-10-13 | 2025-05-01 | 日商衛材R&D企管股份有限公司 | 抗體－藥物軛合物代謝物 |
| WO2025106586A1 (en) * | 2023-11-13 | 2025-05-22 | Luxvitae Therapeutics Inc. | Macrocyclic ketone compounds and applications thereof |
| WO2025228172A1 (zh) * | 2024-04-28 | 2025-11-06 | 上海拓济医药有限责任公司 | 艾日布林衍生物及其抗体药物偶联物和医药用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5338865A (en) * | 1992-03-12 | 1994-08-16 | President And Fellows Of Harvard College | Synthesis of halichondrin B and norhalichondrin B |
| US5436238A (en) | 1992-03-12 | 1995-07-25 | President And Fellows Of Harvard College | Halichondrins and related compounds |
| GB9206244D0 (en) * | 1992-03-23 | 1992-05-06 | Pharma Mar Sa | Cytotoxic compound from a marine sponge |
| US5426194A (en) * | 1993-01-19 | 1995-06-20 | Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University | Isolation and structure of Halistatin 1 |
| HU227912B1 (en) | 1998-06-17 | 2012-05-29 | Eisai R & D Man Co | Halichondrin analogs and methods of their use and preparation |
| US6653341B1 (en) * | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| PL2522663T3 (pl) | 2004-06-03 | 2015-08-31 | Eisai R&D Man Co Ltd | Produkty pośrednie do otrzymywania halichondryny B |
| CN108948039B (zh) | 2007-10-03 | 2021-12-31 | 卫材R&D管理有限公司 | 用于合成软海绵素b类似物的中间体和方法 |
| US20090203771A1 (en) | 2007-11-16 | 2009-08-13 | Eisai R&D Management Co., Ltd. | Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate |
| CN105801599A (zh) | 2008-04-04 | 2016-07-27 | 卫材R&D管理有限公司 | 软海绵素b类似物 |
| CN102803254B (zh) | 2010-01-26 | 2016-09-14 | 卫材R&D管理有限公司 | 用于软海绵素b类似物合成的呋喃并[3,2-b]吡喃衍生物 |
-
1999
- 1999-06-16 HU HU0103357A patent/HU227912B1/hu active Protection Beyond IP Right Term
- 1999-06-16 AT AT99928746T patent/ATE502932T1/de active
- 1999-06-16 KR KR1020007014229A patent/KR100798600B1/ko not_active Expired - Lifetime
- 1999-06-16 CA CA002335300A patent/CA2335300C/en not_active Expired - Lifetime
- 1999-06-16 DE DE201112100031 patent/DE122011100031I1/de active Pending
- 1999-06-16 CA CA2632433A patent/CA2632433C/en not_active Expired - Lifetime
- 1999-06-16 EP EP10010772A patent/EP2277873B1/en not_active Expired - Lifetime
- 1999-06-16 CA CA2755266A patent/CA2755266C/en not_active Expired - Lifetime
- 1999-06-16 AU AU45739/99A patent/AU762998B2/en not_active Expired
- 1999-06-16 CN CN99809658XA patent/CN1216051C/zh not_active Expired - Lifetime
- 1999-06-16 EP EP10010774A patent/EP2272840B1/en not_active Expired - Lifetime
- 1999-06-16 WO PCT/US1999/013677 patent/WO1999065894A1/en not_active Ceased
- 1999-06-16 US US09/334,488 patent/US6214865B1/en not_active Expired - Lifetime
- 1999-06-16 DE DE69943296T patent/DE69943296D1/de not_active Expired - Lifetime
- 1999-06-16 BR BRPI9911326A patent/BRPI9911326B8/pt not_active IP Right Cessation
- 1999-06-16 EP EP99928746A patent/EP1087960B1/en not_active Expired - Lifetime
- 1999-06-16 PT PT99928746T patent/PT1087960E/pt unknown
- 1999-06-16 JP JP2000554719A patent/JP4454151B2/ja not_active Expired - Lifetime
- 1999-06-16 NZ NZ508597A patent/NZ508597A/en not_active IP Right Cessation
- 1999-06-16 EP EP10010773A patent/EP2272839B1/en not_active Expired - Lifetime
- 1999-06-16 IL IL13996099A patent/IL139960A0/xx active Protection Beyond IP Right Term
- 1999-06-16 DK DK99928746.9T patent/DK1087960T3/da active
-
2000
- 2000-10-02 US US09/677,485 patent/US6365759B1/en not_active Expired - Lifetime
- 2000-12-04 ZA ZA200007159A patent/ZA200007159B/en unknown
- 2000-12-12 NO NO20006316A patent/NO328280B1/no not_active IP Right Cessation
-
2001
- 2001-04-26 US US09/843,617 patent/US6469182B1/en not_active Expired - Lifetime
-
2009
- 2009-10-26 NO NO20093217A patent/NO331183B1/no active Protection Beyond IP Right Term
-
2010
- 2010-08-12 US US12/855,412 patent/US8148554B2/en not_active Expired - Fee Related
-
2011
- 2011-06-01 CY CY20111100530T patent/CY1111516T1/el unknown
- 2011-08-12 CY CY2011010C patent/CY2011010I1/el unknown
- 2011-08-17 LU LU91854C patent/LU91854I2/fr unknown
- 2011-09-02 BE BE2011C028C patent/BE2011C028I2/fr unknown
- 2011-09-09 FR FR11C0038C patent/FR11C0038I2/fr active Active
- 2011-09-16 NO NO2011018C patent/NO2011018I1/no unknown
- 2011-12-14 NO NO2011026C patent/NO2011026I2/no unknown
-
2022
- 2022-06-03 NO NO2022019C patent/NO2022019I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20006316D0 (no) | Makrocykliske analoger og fremgangsmåter for fremstilling og anvendelse derav | |
| DE69925133D1 (de) | Pyrrolobenzodiazepine | |
| TR200200579T2 (tr) | Amino-tirazolpiridin türevleri. | |
| DK0896533T3 (da) | Pentafluorbenzensulfonamider og analoger | |
| DK1414828T3 (da) | Antitumoranaloger | |
| DE69433784D1 (de) | 9-(Substituiertes Glycyl)amido-6-(substituiert)-5-hydroxy-6-deoxytetracycline | |
| HUP0000979A1 (hu) | FK-506 jelű vegyületet és származékait tartalmazó gyógyászati készítmények | |
| CY1108522T1 (el) | Μεθοδος συνθεσης της περινδοπριλης και των φαρμακευτικως αποδεκτων αλατων της | |
| FI933568A0 (fi) | 9-((substituerad glycyl)amido)-6-demetyl-6-deoxitetracykliner | |
| NO20014925D0 (no) | Farmasöytiske forbindelser | |
| DE60121461D1 (de) | Kondensierte pyridoindolderivate | |
| ES2134801T3 (es) | Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso. | |
| ES556864A0 (es) | Procedimiento para la obtencion de benzopiranos sustituidos. | |
| DK0736029T3 (da) | Antikonvulsive pseudofructopyranosesulfamater | |
| BR0104358A (pt) | Formulações de taxana tendo solubilidade aperfeiçoada | |
| PT1362844E (pt) | Análogo da benzilamina | |
| DE60121048D1 (de) | PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE | |
| FI952420A0 (fi) | Glukopyranosidibentsotiofeenit | |
| DK0520372T3 (da) | Inositol-phosphat-analoger som calciumantagonistiske stoffer | |
| FI901277A0 (fi) | 2,5,6,7-tetranor-4,8-inter-m-fenylen pg1z-derivativ. | |
| ATE282608T1 (de) | Chinoxalindionen | |
| PT878195E (pt) | Utilizacao de um composto 2-aroil-3-arilbenzo(b)tiofeno para a reducao de fibrinogenio | |
| ES2086395T3 (es) | Fosfolipidos para el tratamiento de esclerosis multiple. | |
| TH27321A (th) | ไบรไคเนติกออก เซไดเอซอล |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: HALAVEN; NAT. REG. NO/DATE: EU/1/11/678/001-2 20110406; FIRST REG. NO/DATE: EU , EU/1/11/678/001-002 20110317 Spc suppl protection certif: 2011026 Filing date: 20111214 |
|
| SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: HALAVEN; NAT. REG. NO/DATE: EU/1/11/678/001-2 20110406; FIRST REG. NO/DATE: EU , EU/1/11/678/001-002 20110317 Spc suppl protection certif: 2011026 Filing date: 20111214 Extension date: 20240616 |
|
| MK1K | Patent expired | ||
| SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: ERIBULIN ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV - FORLENGET SPC; NAT. REG. NO/DATE: EU/1/11/678/001-2 20110406; FIRST REG. NO/DATE: EU/1/11/678/001-002 20110317 Spc suppl protection certif: 2022019 Filing date: 20220603 |
|
| SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: ERIBULIN ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV - FORLENGET SPC; REG. NO/DATE: EU/1/11/678 20220603 Spc suppl protection certif: 2022025 Filing date: 20220613 |
|
| SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: ERIBULIN ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV - FORLENGET SPC; NAT. REG. NO/DATE: EU/1/11/678/001-2 20110406; FIRST REG. NO/DATE: EU/1/11/678/001-002 20110317 Spc suppl protection certif: 2022019 Filing date: 20220603 Extension date: 20241216 |